Avapritinib Rollover Study
ConditionMastocytosis, Systemic
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorBlueprint Medicines Corporation
About this trial
The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.
Eligibility criteria
Qualifiers
Participated in a Blueprint Medicines sponsored avapritinib clinical study. The Sponsor reserves the right to not roll over patients who have been on drug hold for an extended time period.
Completed End of Trial / End of Study (EOT/EOS) visit in the parent study and demonstrated compliance with the parent study requirements.
Continue to clinically benefit from treatment with avapritinib.
Able to give written informed consent.
Disqualifiers
Participant is participating in another interventional study.
Participant is unwilling or unable to comply with study procedures and study restrictions.
Participant is breastfeeding.
Trial design
Treatments tested in this trial
- Avapritinib
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov